Oncology  Conference update

ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium

Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer

Prof. Valentina Guarneri

Prof. Valentina Guarneri
Prof. Matteo Lambertini

Prof. Matteo Lambertini
Prof. Federico Rojo

Prof. Federico Rojo

Publication Date

Mar 2024

menu

In this conference update video, Prof. Valentina Guarneri, Prof. Matteo Lambertini, and Prof. Federico Rojo summarise the key points presented at the highly anticipated EBCC-14 Industry Satellite Symposium and review the current and future treatment landscape for ER+/HER2- advanced breast cancer, with a focus on the metastatic luminal subtype.

 

Topics of discussion include:

  • Overview of the ESMO metastatic breast cancer living guidelines
  • Impact of endocrine resistance and sensitivity
  • The benefit of biomarker-selected endocrine-based therapies in ER+/HER2- advanced breast cancer
  • ESR1 mutation: clinical significance and testing strategies

 

Clinical Takeaways

  • Biomarker-selected endocrine therapies show greater PFS benefits in specific patient subgroups
  • Elacestrant, the first oral SERD to obtain FDA & EMA approval, demonstrates optimal efficacy in ESR1-mutated ER+/HER2- mBC following CDK4/6i treatment
  • Capivasertib, FDA-approved based on the CAPItello-291 study for AKT-pathway altered population, awaits EMA approval as of March 2024
  • ESR1 mutation, holding both prognostic and predictive value, warrants testing upon ET recurrence or progression, using tissue or liquid biopsy

Educational Objectives

  • Conduct a thorough evaluation to determine the underlying causes of HR-positive, HER2-negative breast cancer progression (with a focus on the metastatic luminal subtype)
  • Know the role and be able to implement genomic testing appropriately
  • Implement optimisation of treatment selection, and make the appropriate sequencing decisions in the context of shared decision making

"Valentina Guarneri, MD, PhD, is Full Professor of Oncology at the University of Padua, Head of the Division of Oncology 2 at the Istituto Oncologico Veneto, and head of the Specialization School in medical Oncology at the University of Padova. She completed her fellowship in Oncology in 2003, and she obtained her PhD Degree in Clinical and Experimental Oncology in 2007. In 2005 she was appointed Assistant Professor of Oncology at the University of Modena and Reggio Emilia, where she also chaired the Breast Unit. In 2005, she also completed a 6-month-research experience at the Department of Breast Medical Oncology, UT. MD Anderson Cancer Center, Houston, Texas, where in 2009 she was Visiting Assistant Professor. In 2014 she was appointed Associate Professor of Oncology at the University of Padua.  Prof Guarneri’s research interest is mainly focused on clinical and translational research for breast cancer patients. She has published more than 200 papers in peer-reviewed journals."

Prof. Valentina Guarneri has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Advisory Role: Eisai, Eli Lilly, Exact Sciences, Gilead, Merck Serono, MSD, Novartis, Olema Oncology.

Speakers bureau: Amgen, Eli Lilly, GSK, Gilead, AstraZeneca, Novartis.

Expert testimony: Eli Lilly

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Menarini Stemline.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology.

Meet the experts

Other programmes of interest

podcast Podcast
Oncology Rare diseases 
Neuroendocrine tumours (NETs) shared decision-making: Exploring the patient journey and individualising treatments

Experts
Dr Mohid S Khan, Sally Jenkins
Endorsed by
CommNETs
NANETS
Neuroendocrine Cancer UK
The Healing NET Foundation
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Sep 2024
NET CONNECT
video Video
Oncology Hemato-oncology 
Early relapsed/refractory multiple myeloma (RRMM): best practices in management

A 3-part video series on managing early RRMM from leading medical experts

Experts
Dr Elena Zamagni, Dr Fredrik Schjesvold, Dr Joseph Mikhael
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Sep 2024
LYMPHOMA & MYELOMA CONNECT
other Other

Episode

2

of 2

episode
Oncology 
Optimising samples for biomarker testing in lung, prostate and gastric cancer

Recommendations for best practice

Experts
Dr Alexander Wyatt, Prof. Frédéric Bibeau
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Aug 2024
PRECISION ONCOLOGY CONNECT
Educational programme supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
publication Publication
Oncology 
Advancing HCC management in Asia: insights from patients and HCPs

Paper published in Journal of Gastrointestinal Cancer

Experts
Prof. Chee-Kiat Tan
  • download Downloadable
    Resources
  • clock 15 MIN
  • calendar Jul 2024
COR2ED
This educational programme is supported by an Independent Educational Grant from Roche.
other Other
Oncology 
Come and visit us in Barcelona at ESMO 2024!

Get your free professional profile photos taken with us at Booth 507

  • clock 1 MIN
  • calendar Jul 2024
COR2ED
micro-learning Micro learning
Oncology Endocrinology Rare diseases 
Tools for optimising treatment & management of advanced NETs

Maximising outcomes for patients with advanced neuroendocrine tumours 

Experts
Prof. Emily Bergsland, Prof. Louis de Mestier
Endorsed by
NANETS
Neuroendocrine Cancer UK
CommNETs
The Healing NET Foundation
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jul 2024
NET CONNECT
Educational programme supported by an Independent Educational Grant from Ipsen.
Explore all programmes